Brief: Sensei Announces New Preclinical Data For SNS-101
31/08/2022 12:57
Aug 31 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS ANNOUNCES NEW PRECLINICAL DATA
DEMONSTRATING FAVORABLE PHARMACOKINETIC AND IMMUNOLOGIC EFFECTS
OF SNS-101, A PH-SELECTIVE VISTA-BLOCKING ANTIBODY
* SENSEI BIOTHERAPEUTICS INC - CO PLANS TO FILE AN IND
DURING
FIRST HALF OF 2023
Source text for Eikon: ID:nGNXc3s0Yn
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)